ABBOTT LABORATORIES — Board/Management Information 2017

Jun 29, 2017

8-K 1 a17-15898_18k.htm 8-K

*UNITED STATES*

*SECURITIES AND EXCHANGE COMMISSION*

*Washington, D. C. 20549*

*FORM 8-K*

*CURRENT REPORT*

*Pursuant to Section 13 or 15(d) of the*

*Securities Exchange Act of 1934*

*June 28, 2017*

Date of Report (Date of earliest event reported)

*ABBOTT LABORATORIES*

(Exact name of registrant as specified in its charter)

Illinois	1-2189	36-0698440
(State or other Jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification No.)

*100 Abbott Park Road*

*Abbott Park, Illinois 60064-6400*

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (224) 667-6100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

SEQ.=1,FOLIO='',FILE='C:\JMS\105569\17-15898-1\task8486985\15898-1-ba.htm',USER='105569',CD='Jun 28 23:23 2017'

*Item 5.02 — Election of Directors*

On June 29, 2017, John G. Stratton was named to the Abbott Laboratories’ Board of Directors, effective immediately.

*Item 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year*

On June 28, 2017, Abbott’s Board of Directors amended the first sentence of Article III, Section 2 of Abbott’s by-laws to provide that Abbott’s Board of Directors shall consist of twelve persons, effective as of June 29, 2017. Abbott’s by-laws previously provided that the Board of Directors consisted of eleven persons.

*Item 9.01 Financial Statements and Exhibits*

Exhibit No.	Exhibit
3.1	By-Laws of Abbott Laboratories, as amended and restated effective June 29, 2017.

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\105569\17-15898-1\task8486985\15898-1-ba.htm',USER='105569',CD='Jun 28 23:23 2017'

*SIGNATURE*

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Brian B. Yoor
Brian B. Yoor
Executive Vice President, Finance and Chief Financial Officer

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\105569\17-15898-1\task8486985\15898-1-ba.htm',USER='105569',CD='Jun 28 23:23 2017'

*EXHIBIT INDEX*

Exhibit No.	Exhibit
3.1	By-Laws of Abbott Laboratories, as amended and restated effective June 29, 2017.

4

SEQ.=1,FOLIO='4',FILE='C:\JMS\105569\17-15898-1\task8486985\15898-1-ba.htm',USER='105569',CD='Jun 28 23:23 2017'